Zai Lab Ltd
$ 19.37
-1.77%
24 Feb - close price
- Market Cap 2,210,010,000 USD
- Current Price $ 19.37
- High / Low $ 19.56 / 18.80
- Stock P/E N/A
- Book Value 6.87
- EPS -1.90
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.29 %
- 52 Week High 44.34
- 52 Week Low 15.96
About
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Analyst Target Price
$43.42
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-07 | 2023-05-09 | 2023-03-01 |
| Reported EPS | -0.33 | -0.37 | -0.45 | -0.8 | -0.42 | -0.8 | -0.5 | -1 | -0.71 | -1.25 | -0.51 | -0.65 |
| Estimated EPS | -0.25 | -0.41 | -0.5475 | -0.6333 | -0.78 | -0.71 | -0.92 | -0.86 | -1.04 | -0.79 | -0.95 | -1.11 |
| Surprise | -0.08 | 0.04 | 0.0975 | -0.1667 | 0.36 | -0.09 | 0.42 | -0.14 | 0.33 | -0.46 | 0.44 | 0.46 |
| Surprise Percentage | -32% | 9.7561% | 17.8082% | -26.3224% | 46.1538% | -12.6761% | 45.6522% | -16.2791% | 31.7308% | -58.2278% | 46.3158% | 41.4414% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZLAB
2026-02-19 07:58:51
Zai Lab (ZLAB) is expected to announce its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting an EPS of ($0.38). The stock is currently trading below its 200-day moving average, and recent insider selling has occurred. Despite mixed analyst ratings, the consensus remains a "Moderate Buy" with a target price of $51.59.
2026-02-17 23:57:30
Zai Lab, a China-focused oncology biotech with Nasdaq-listed ADRs, is seeing its stock gain due to U.S. FDA progress despite ongoing regulatory and geopolitical risks. Analysts highlight significant revenue growth potential and a solid cash runway, positioning ZLAB as a potential diversifier for U.S. biotech portfolios, though it trades at a discount compared to peers. The article suggests that if investors believe in China's investability and Zai Lab's pipeline execution, the current risk/reward is asymmetrical.
2026-02-15 08:57:30
Zai Lab Ltd (ZLAB) is advancing its new solid tumor drug, ZL-1310, with an ongoing Phase 1b/2 clinical study. This trial aims to assess the safety and anti-tumor activity of ZL-1310 as a potential treatment for advanced solid tumors. While the study signals Zai Lab's investment in early-stage oncology, significant stock impact is not expected until efficacy or safety data are released.
2026-02-14 09:57:27
Zai Lab (ZLAB) has experienced mixed share price performance, with significant declines over three and five years, despite recent short-term gains. A Discounted Cash Flow (DCF) analysis suggests the stock is 80.6% undervalued, estimating an intrinsic value of US$103.33 per share compared to its current US$20.03. However, based on Price/Sales, the stock appears overvalued with a P/S of 5.08x against a fair ratio of 3.65x.
2026-02-14 09:28:27
This article analyzes Zai Lab's (ZLAB) current share price against its potential intrinsic value, following multi-year declines. Using a Discounted Cash Flow (DCF) analysis, the stock appears significantly undervalued, while a Price-to-Sales (P/S) ratio suggests it is overvalued. The article encourages investors to use different valuation narratives to form their own conclusions.
2026-02-11 13:57:44
Zai Lab Ltd will hold a board meeting on February 26, 2026, to approve its 2025 annual financial results, prepared under U.S. GAAP. These results will be published the same day, followed by a teleconference and webcast for investors. The company also commits to providing a Hong Kong-compliant annual results announcement, including a U.S. GAAP to IFRS reconciliation, by March 31, 2026.
